RAC Premarket Submission Pathways Questions and Answers 1 — Questions and Answers
Question 1: A medical device manufacturer has developed a novel device for diagnosing a rare neurological condition. There is no legally marketed predicate device available. The device presents a low-to-moderate risk profile. Which of the following premarket submission pathways is the most appropriate for this device?
- Premarket Approval (PMA)
- De Novo Classification Request (Correct answer)
- Premarket Notification (510(k))
- Humanitarian Device Exemption (HDE)
Correct answer: De Novo Classification Request
The De Novo pathway is designed for novel, low-to-moderate risk devices for which there is no existing predicate device. This process allows the FDA to classify the new device as Class I or II, making it a predicate for future submissions. A 510(k) is not possible without a predicate. A PMA is for high-risk (Class III) devices. An HDE is for devices that treat or diagnose conditions affecting a very small number of patients per year, and while this might apply, the De Novo pathway is the primary route for novel, lower-risk devices seeking classification.
Question 2: A company is planning to market a new cardiac stent, a life-sustaining device that will be permanently implanted. This type of device is considered high-risk (Class III). Which submission pathway to the FDA will be required?
- Premarket Approval (PMA) (Correct answer)
- Premarket Notification (510(k))
- De Novo Classification Request
- Investigational Device Exemption (IDE)
Correct answer: Premarket Approval (PMA)
Premarket Approval (PMA) is the most stringent regulatory pathway and is required for Class III devices, which are high-risk devices that are life-sustaining, life-supporting, or present a potential unreasonable risk of illness or injury. A cardiac stent falls into this category. The PMA process requires a demonstration of the device's safety and effectiveness through extensive scientific, preclinical, and clinical data.
Question 3: The central principle of a Premarket Notification (510(k)) submission is demonstrating:
- Novelty and innovation
- Cost-effectiveness compared to existing treatments
- Substantial equivalence to a predicate device (Correct answer)
- Probable benefit outweighs the risk of use
Correct answer: Substantial equivalence to a predicate device
The core of a 510(k) submission is to demonstrate that the new device is 'substantially equivalent' to a legally marketed device (the predicate device) in terms of intended use, technological characteristics, and safety and effectiveness. This means the new device is at least as safe and effective as the predicate.
Question 4: A manufacturer develops a device intended to treat a condition that affects fewer than 8,000 people in the United States annually. Due to the small patient population, conducting large-scale clinical trials to prove effectiveness is not feasible. Which pathway offers a potential route to market for such a device?
- Abbreviated 510(k)
- De Novo Classification Request
- Product Development Protocol (PDP)
- Humanitarian Device Exemption (HDE) (Correct answer)
Correct answer: Humanitarian Device Exemption (HDE)
The Humanitarian Device Exemption (HDE) pathway is specifically designed for devices intended to treat or diagnose diseases or conditions affecting fewer than 8,000 individuals in the U.S. per year. This pathway exempts the device from the effectiveness requirements of a PMA, but the applicant must demonstrate that the probable benefit to health outweighs the risks and that there is no comparable device available.
Question 5: A company modifies its previously cleared 510(k) device. The change involves a minor alteration to the user interface software that does not affect the device's intended use, fundamental scientific technology, or safety and effectiveness. Which of the following is the most appropriate course of action?
- Submit a new Premarket Approval (PMA) application.
- Submit a De Novo request for the modified device.
- Document the change in the Design History File and assess if a new 510(k) is needed. (Correct answer)
- Immediately recall the product from the market.
Correct answer: Document the change in the Design History File and assess if a new 510(k) is needed.
For modifications to a 510(k)-cleared device, the manufacturer must assess whether the change could significantly affect the safety or effectiveness of the device. If the change is minor and does not trigger this threshold, a new 510(k) may not be required. The proper procedure is to document the change and the justification for not submitting a new 510(k) in the quality system records, such as the Design History File, per 21 CFR 820.
Question 6: Which of the following statements BEST distinguishes the Premarket Approval (PMA) pathway from the 510(k) pathway?
- A 510(k) results in an 'approval' letter, while a PMA results in a 'clearance' letter.
- The PMA pathway requires a demonstration of safety and effectiveness through clinical data, whereas a 510(k) relies on substantial equivalence to a predicate. (Correct answer)
- 510(k) submissions are only for Class I devices, while PMA submissions are for Class II and III devices.
- The standard review timeline for a 510(k) is 180 days, whereas for a PMA it is 90 days.
Correct answer: The PMA pathway requires a demonstration of safety and effectiveness through clinical data, whereas a 510(k) relies on substantial equivalence to a predicate.
The fundamental difference lies in the evidence required. The PMA process requires manufacturers to provide valid scientific evidence, typically including clinical trial data, to independently demonstrate a reasonable assurance of the device's safety and effectiveness. In contrast, the 510(k) pathway requires a demonstration of substantial equivalence to a legally marketed predicate device, leveraging the predicate's established safety and effectiveness profile.
RAC Premarket Submission Pathways Questions and Answers 1
A medical device manufacturer has developed a novel device for diagnosing a rare neurological condition.
There is no legally marketed predicate device available.
The device presents a low-to-moderate risk profile.
Which of the following premarket submission pathways is the most appropriate for this device?